BACKGROUND: Because infection with any of the 4 Dengue virus serotypes may elicit both protective neutralizing antibodies and nonneutralizing antibodies capable of enhancing subsequent heterotypic Dengue virus infections, the greatest risk for severe dengue occurs during a second, heterotypic Dengue virus infection. It remains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanced when administered to Dengue-immune individuals. METHODS: We recruited 36 healthy adults who had previously received a monovalent live Dengue virus vaccine 0.6-7.4 years earlier. Participants were assigned to 1 of 4 cohorts and were randomly chosen to receive placebo or a heterotypic vaccine. The level of replication, safety, and immunogenicity of the heterotypic vaccine virus was compared with that of Dengue virus immunologically naive vaccinees. RESULTS: Vaccine virus replication and reactogenicity after monovalent Dengue virus vaccination in naive and heterotypically immune vaccinees was similar. In contrast to naive vaccinees, the antibody response in heterotypically immune vaccinees was broadly neutralizing and mimicked the response observed by natural secondary Dengue virus infection. CONCLUSIONS: Enhanced replication of these live attenuated Dengue virus vaccines was minimal in heterotypically immune vaccinees and suggests that the further evaluation of these candidate vaccines in populations with preexisting DENV immunity can proceed safely.
RCT Entities:
BACKGROUND: Because infection with any of the 4 Dengue virus serotypes may elicit both protective neutralizing antibodies and nonneutralizing antibodies capable of enhancing subsequent heterotypic Dengue virus infections, the greatest risk for severe dengue occurs during a second, heterotypic Dengue virus infection. It remains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanced when administered to Dengue-immune individuals. METHODS: We recruited 36 healthy adults who had previously received a monovalent live Dengue virus vaccine 0.6-7.4 years earlier. Participants were assigned to 1 of 4 cohorts and were randomly chosen to receive placebo or a heterotypic vaccine. The level of replication, safety, and immunogenicity of the heterotypic vaccine virus was compared with that of Dengue virus immunologically naive vaccinees. RESULTS: Vaccine virus replication and reactogenicity after monovalent Dengue virus vaccination in naive and heterotypically immune vaccinees was similar. In contrast to naive vaccinees, the antibody response in heterotypically immune vaccinees was broadly neutralizing and mimicked the response observed by natural secondary Dengue virus infection. CONCLUSIONS: Enhanced replication of these live attenuated Dengue virus vaccines was minimal in heterotypically immune vaccinees and suggests that the further evaluation of these candidate vaccines in populations with preexisting DENV immunity can proceed safely.
Authors: Wellington Sun; Robert Edelman; Niranjan Kanesa-Thasan; Kenneth H Eckels; J Robert Putnak; Alan D King; Huo-Shu Houng; Douglas Tang; John M Scherer; Charles H Hoke; Bruce L Innis Journal: Am J Trop Med Hyg Date: 2003-12 Impact factor: 2.345
Authors: A P Durbin; R A Karron; W Sun; D W Vaughn; M J Reynolds; J R Perreault; B Thumar; R Men; C J Lai; W R Elkins; R M Chanock; B R Murphy; S S Whitehead Journal: Am J Trop Med Hyg Date: 2001-11 Impact factor: 2.345
Authors: D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak Journal: J Infect Dis Date: 2000-01 Impact factor: 5.226
Authors: Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty Journal: J Infect Dis Date: 2004-03-01 Impact factor: 5.226
Authors: Beth D Kirkpatrick; Anna P Durbin; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Sean A Diehl; Dan Elwood; Adrienne P Jarvis; Beulah P Sabundayo; Caroline E Lyon; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Steven S Whitehead Journal: J Infect Dis Date: 2015-03-22 Impact factor: 5.226
Authors: Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead Journal: J Infect Dis Date: 2013-01-17 Impact factor: 5.226
Authors: Kathryn B Anderson; Robert V Gibbons; Derek A T Cummings; Ananda Nisalak; Sharone Green; Daniel H Libraty; Richard G Jarman; Anon Srikiatkhachorn; Mammen P Mammen; Buddhari Darunee; In-Kyu Yoon; Timothy P Endy Journal: J Infect Dis Date: 2013-08-20 Impact factor: 5.226
Authors: Janet C Lindow; Anna P Durbin; Stephen S Whitehead; Kristen K Pierce; Marya P Carmolli; Beth D Kirkpatrick Journal: Vaccine Date: 2013-06-02 Impact factor: 3.641